News|Articles|May 2, 2004
- Pharmaceutical Technology-05-02-2004
- Volume 28
- Issue 5
aaiPharma Situation Underscores The Need for Due Diligence
Author(s)Jim Miller
Sponsors who have been lax in performing financial due diligence on their contractors have been given a wake-up call by the recent developments at aaiPharma.
Advertisement
Articles in this issue
over 21 years ago
In The Spotlight-May 2004over 21 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 21 years ago
Prepare for Bar Codingover 21 years ago
Excipient Functionalityover 21 years ago
May 2004Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Using AI and Molecular Dynamics to Overcome the Poor Solubility Challenge
2
Targeted high resolution metabolite screening workflows
3
Why Context Matters in Validating Biomarker Assays for Bioanalysis
4
Confident characterization and identification of glucuronide metabolites using diagnostic fragments from electron activated dissociation (EAD)
5
